A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix - A Gynecologic Oncology Group study

Authors
Plaxe, SC Blessing, JA Lucci, JA Hurteau, JA
Citation
Sc. Plaxe et al., A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix - A Gynecologic Oncology Group study, INV NEW DR, 19(1), 2001, pp. 77-80
Citations number
10
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
INVESTIGATIONAL NEW DRUGS
ISSN journal
01676997 → ACNP
Volume
19
Issue
1
Year of publication
2001
Pages
77 - 80
Database
ISI
SICI code
0167-6997(200102)19:1<77:APITOP>2.0.ZU;2-O
Abstract
Purpose: The Gynecologic Oncology Group performed a Phase II study to deter mine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered at a dose of 750 mg/m(2) intravenously over three hours every three weeks. Results: Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic. Con clusion: PZA at the dose and schedule employed has insignificant activity i n this population.